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Cellular proteinWe examined the antiviral activity of ADAR1 against HIV-1. Our results indicated that ADAR1 in a transfec-
tion system inhibited production of viral proteins and infectious HIV-1 in various cell lines including 293T,
HeLa, Jurkat T and primary CD4+ T cells, and was active against a number of X4 and R5 HIV-1 of different
clades. Further analysis showed that ADAR1 inhibited viral protein synthesis without any effect on viral
RNA synthesis. Mutational analysis showed that ADAR1 introduced most of the A-to-G mutations in the rev
RNA, in the region of RNA encoding for Rev Response Element (RRE) binding domain and in env RNA.
These mutations inhibited the binding of rev to the RRE and inhibited transport of primary transcripts like
gag, pol and env from nucleus to cytoplasm resulting in inhibition of viral protein synthesis without any effect
on viral RNA synthesis. Furthermore, ADAR1 induced mutations in the env gene inhibited viral infectivity.
© 2011 Elsevier Inc. All rights reserved.Introduction
ADAR1 (Adenosine Deaminase Acting on RNA 1), an RNA editing
enzyme, catalyzes hydrolytic deamination of adenosine to inosine
(A-to-I) in completely or partially double-stranded RNA (Hough and
Bass, 1994; Kim et al., 1994; O'Connell and Keller, 1994; Patterson
and Samuel, 1995). This has a number of effects. The A-to-I substitu-
tion affects pre-mRNA splicing by changing the splicing site and de-
creases the binding of RNA to protein resulting in functional
changes of the protein (Bass, 2002; Samuel, 2003). Furthermore, dur-
ing mRNA translation, Inosine is recognized as Guanosine and there-
fore it incorporates incorrect amino acid sequence (Bass, 2002;
Samuel, 2003). Because of these pluripotent properties of ADAR1, it
disrupts replication of a number of RNA viruses. ADAR1 inhibits rep-
lication of hepatitis delta virus by editing of adenosine to inosine in
pre-mRNA of hepatitis delta virus which eventually affects splicing
of untranslated regions (Patterson and Samuel, 1995; Polson et al.,
1996; Sato et al., 2001). ADAR1 was also known to edit double-
stranded RNA found in the measles virus, which inhibited virus as-
sembly and release from cells, leading to a persistent infection and
development of fatal neuropathic measles infection (Horikami and
Moyer, 1995). Taylor et al. (2005) showed that ADAR1-induced viral
RNA editing inhibited Hepatitis C viral replication (Taylor et al.,
2005). Recently Suspene et al. have shown ADAR1 induced mutation
in seasonal inﬂuenza and attenuated measles viruses.iseases and Microbiology, 426
SA. Fax: +1 412 624 4953.
rights reserved.Since HIV-1 genome has several putative double stranded secondary
RNA structures throughout its genome, HIV-1 RNA was considered a po-
tential target forADAR1. Therefore, in this reportwe investigated the anti-
viral effect of ADAR1 on HIV-1. We provided evidence that ADAR1
inhibited HIV-1 protein synthesis and viral infectivity in a variety of cells
and against HIV-1 of different tropisms and different clades. We further
demonstrated that such antiviral activity was at the post transcriptional
stage of HIV-1 replication and that ADAR1-induced mutation at the rev
and env RNA may be responsible for such posttranscriptional inhibition
of viral protein synthesis. In elucidating themechanismofADAR1 induced
inhibition of HIV-1 protein synthesis we found that ADAR1 induced A-to-
G mutations in rev inhibited its transport activity of primary transcripts
gag, pol and env from the nucleus to cytoplasm and thereby inhibited
viral protein synthesis without any effect on viral RNA synthesis. ADAR1-
induced mutations in the env gene further attenuate viral infectivity.Results
ADAR1 inhibits HIV-1 protein synthesis and viral infectivity
In order to evaluate the effect of ADAR1 on HIV-1 production,
293 T cells were co-transfectedwith 0.1 μg pNL4.3 HIV-1 DNA and differ-
ent amount of ADAR1 DNA. In each transfection assay (this one and sub-
sequent ones), cells were also co-transfected with a luciferase-
expressing plasmid DNA to control transfection efﬁciency. The expres-
sion of ADAR1 p150 from transfected ADAR1 DNA was analyzed
by Western Blot and normalized against β-actin loading control to
show the relative intensity of ADAR1 p150 expression (Supplemental
266 N. Biswas et al. / Virology 422 (2012) 265–277Fig. 1A). Following 48 h of transfection, viral protein synthesis was quan-
tiﬁed by measuring HIV-1 p24 in culture supernatant and intracellular
HIV-1 p24 production in a cell extract by ELISA. ADAR1 inhibitedextracellular (Fig. 1A) and intracellular (Fig. 1B) HIV-1 p24 production
in a dose dependent manner. With 0.7 μg of ADAR1 containing plasmid
there was an 8 fold reduction of extracellular HIV-1 p24 production in
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tion of viral protein synthesis was not due to cellular toxicity by ADAR1
as evidenced by no change in viable cell numbers in the presence and ab-
sence of ADAR1 ( MTT assay, data not shown). The antiviral activity of
ADAR1 was further evaluated in two other cell lines, Jurkat T and HeLa
cells. Inhibition of viral p24 production in culture supernatant (Fig. 1C)
and intracellular p24 (data not shown) was also observed in Jurkat
T cells and in HeLa cells (data not shown).
To further demonstrate speciﬁcity of ADAR1 mediated inhibition of
HIV-1 synthesis, shRNA mediated silencing of ADAR1 was used to
block ADAR1 mediated antiviral activity. First we evaluated the effect
of shRNA on the expression of ADAR1. 293 T cells were co-transfected
with ADAR1 in the presence and absence of two shRNA constructs tar-
geting human ADAR1 p150 RNA (sh1724 and sh228). As shown in Sup-
plemental Fig. 1B, both of the shRNA constructs (sh1724 and sh228)
were able to inhibit expression of ADAR1 p150. As a control a shRNA
526 against an unrelated RNA showed no inhibition of human ADAR1
expression. As shown in Fig. 1D, shRNA against ADAR1 (sh1724 and
sh228) blocked ADAR1 mediated inhibition of HIV-1 protein synthesis.
Next, we examined the effect of ADAR1 on HIV−1 protein synthesis
in primary CD4 enriched T cells in which viral challenge was done by in-
fection rather than by transfection. Since expression of ADAR1 is very low
in immune cells like T cells, B cells and macrophages (Yang et al., 2003),
we transfected primary CD4 enriched T cells with ADAR1 expressing
DNA followed by infection with HIV-1. For this purpose PHA stimulated
CD8 depleted PBMC were nucleofected with 2 μg of plasmid encoding
ADAR1. The cells were infected 48 h post-transfection with 0.5 ng/μl,
and 1 ng/μl of pNL4.3 virus for 2 h. Virus production in culture superna-
tant was measured using p24 ELISA 72 h post-infection. As shown in
Fig. 1E, ADAR1 inhibited HIV-1 protein synthesis in CD4 enriched T cells.
Next, the inhibitory effect of ADAR1 was examined in 293 T cells
against HIV-1 of different tropisms and different clades. As shown in
Fig. 1F, ADAR1 inhibited production of clade C HIV-1 (pIndie C) in cul-
ture supernatant, however the antiviral activity was more pro-
nounced against pNL4.3 (clade B) than pIndie C (clade C). ADAR1
also inhibited production of macrophage tropic HIV-1 AD8 and dual
tropic HIV-1 89.6 (Fig. 1F).
The infectivity of the virus from the culture supernatant of 293 T
cells transfected with ADAR1 plasmid or control plasmid (from
Fig. 1A) was then evaluated for infectivity in TZM-bl cells. A dose-
dependent reduction in the viral infectivity in the presence of
ADAR1 was observed (Fig. 1G), even though equal amount of virus
(as measured by p24) was used.
We then examined the effect of ADAR1 expression on infectivity of
HIV-1 produced in culture supernatant from 293 T cells transfected
with HIV-1 having different tropisms and of different clades (used
in Fig. 1F). Equal amounts of viruses (as measured by p24) obtained
from 293 T cells transfected with the ADAR1 plasmid or the control
plasmid were used to infect TZM-bl cells. As shown in Supplemental
Fig. 2, viral infectivity was signiﬁcantly inhibited in the presence of
ADAR1, regardless of viral tropisms and clades.
Induction of ADAR1 expression in Jurkat cells following IFNα treatment
Since ADAR1 is an IFNα-inducible enzyme, the expression of
ADAR1 p150 is expected to increase in the presence of IFNα treatmentFig. 1. Effect of ADAR1 onHIV-1 protein synthesis and infectivity. 293 T cellswere co-transfected
Luciferase plasmid. HIV-1 production and infectivitywere evaluated after 48 h. Viral protein synth
HIV p24 production (Panel B). Results are given asmeans±standard deviation.Measurement of
increasing amounts of ADAR1 in three independent experiments are shown (Panel C). 293 T cell
shRNA1724 and526. Viral protein synthesiswasmonitored bymeasuringHIVp24 in culture supe
ADAR1. After 48 h cellswere infectedwith 0.5 ng/μl and 1 ng/μl, of pNL4.3 virus for 2 h. HIV-1 prod
of p24 production in the presence of ADAR1. 0.0475 ng of p24 valuewas considered as 100%whe
ml virus was added (Panel E). Production of extracellular HIV-1 p24 in 293 T cells co-transfected
(Panel F). 3 ng HIV-1 p24 equivalent viruses obtained from 293 T cells transfected with pNL4.3
Productive infection was monitored after 48 h by measurement of luciferase activity. * indicates(Patterson et al., 1995). Jurkat cells were stimulated with different con-
centration of IFNα (100units/ml, 500units/ml and 1000 units/ml) for
various lengths of time (12 h, 24 h, 48 h and 72 h). At the indicated
time after interferon treatment, cells were lysed and a Western blot
was performed using amonoclonal antibody against ADAR1 to evaluate
the level of IFNα-induced expression of endogenous ADAR1. Intracellu-
lar ADAR1 p150 expressionwas observed after 24 h of IFNα stimulation
with 100, 500 and 1000 units/ml of IFNα and it increased over time
(Fig. 2A). As ADAR1 p150 is an IFNα-inducing enzyme, the expression
of p150 form was increased with increasing amount of IFNα.
To check whether ADAR1 expression induced by IFNα could inhib-
it the synthesis of HIV-1 viral protein, cells were induced with 500
units/ml and 1000 units/ml IFNα. After 72 h of interferon treatment
cells were infected with 500 ng/ml of pNL4.3 virus. In presence of
500 units/ml and 1000 units/ml of IFNα approximately 25% and 40%
reduction in the viral protein synthesis was observed, respectively,
as compared to the unstimulated cells (Fig. 2B). To verify that the in-
hibition of HIV-1 synthesis was due to IFNα-induced expression of
ADAR1, cells were induced with 500 units/ml and 1000 units/ml
IFNα for 72 h. After 72 h, cells were transfected with shRNA against
ADAR1 (sh228) and shRNA against an unrelated RNA (sh526). As
shown in Fig. 2C, IFNα-induced inhibition of viral protein synthesis
was at least partially reversed in the presence of shRNA against
ADAR1, but not in the presence of shRNA against an unrelated RNA.
These results indicate that the inhibition of HIV-1 protein synthesis
in presence of IFNα was due to expression of endogenous ADAR1 in
Jurkat cells (Fig. 2C).
ADAR1 inhibits HIV-1 viral protein synthesis
Since expression of ADAR1 inhibited extracellular and intracellu-
lar p24 production, we investigated the effect of ADAR1 on produc-
tion of other HIV-1 protein. 293 T cells were co-transfected with
pNL4.3 plasmid (0.1 μg), and ADAR1 (0.7 μg) or control empty vector
(pcDNA 3.1, 0.7 μg). Cells were also co-transfected with a luciferase-
expressing plasmid DNA to control transfection efﬁciency. Western
blots were performed using monoclonal antibody against gp120 and
polyclonal serum from a single HIV-infected patient to determine
the expression of p24, Pol and Env gp120 proteins in virus from cul-
ture supernatant as well as lysates from cells transfected with or
without ADAR1 plasmid.
As shown in Fig. 3A, the expression of HIV-1 p24, Env gp41, p65
Pol, and Env gp160 proteins in the presence of ADAR1 expression
was signiﬁcantly reduced in culture supernatants as compared to su-
pernatants of cells not expressing ADAR1. The reduction of Env pro-
tein in virion in the presence of ADAR1 expression was further
conﬁrmed by Western blot analysis using monoclonal antibody
against Env gp120 (Fig. 3B). In the presence of ADAR1, there was a
9-fold decrease in the expression of virion associated HIV-1 gp120
protein in culture supernatant (Fig. 3B). In addition, Western blot
analysis of cell lysates using a polyclonal serum from an HIV-1
infected patient showed that the levels of p24 Gag and p65 Pol pro-
tein were signiﬁcantly reduced in the presence of ADAR1 (Fig. 3C).
Similarly, as shown in Fig. 3D, a 7 fold decrease in the expression of
intracellular gp120 was observed in the presence of ADAR1 compared
to the control DNA. However, ADAR1 showed no effect on the synthe-
sis of an accessory protein Nef (Fig. 3E).These results indicated thatwith 0.1 μg pNL4.3 plasmid and different amounts of ADAR1 plasmid and the control Renilla
esiswasmonitored bymeasuringHIV p24 in culture supernatant (Panel A) and intracellular
extracellular HIV-1 p24 production in transfected Jurkat cells in the absence and presence of
s were transfected with 0.1 μg pNL4.3, 0.5 μg ADAR1 in presence and absence of shRNA 228,
rnatant 48 hpost transfection (Panel D). CD8depleted PBMCwere nucleofectedwith 2 μg of
uctionwas evaluated after 72 h using p24 ELISA andcalculating the percentage of inhibition
re 0.5 ng/ml viruswas added and0.333 ng of p24 valuewas considered as 100%where 1 ng/
with HIV-1 89.6, AD8, pIndie C or pNL4.3 plasmids and increasing amount of ADAR1 DNA
alone or together with ADAR1 from Panel B were used to infect TZM-bl cell line (Panel G).
there is a signiﬁcant difference (Pb0.05) compared to the respective control.
Fig. 2. Expression of endogenous ADAR1 in Jurkat T cell line and its inhibitory capacity on HIV-1 protein synthesis. Jurkat T cells were stimulated with 100units/ml, 500units/ml and
1000 units/ml IFNα for different length of time, 12 h, 24 h, 48 h and 72 h. At each time point cells were harvested and expression of ADAR1 was determined by Western blot using
ADAR1 antibody and normalized against β-actin loading control. Relative intensity of ADAR1 p150 in the blot was quantitated (Panel A). Jurkat cells were stimulated with IFN α for
72 h and then infected with 500 ng/ml of pNL4.3 virus. After 48 h viral protein synthesis was monitored by measuring the HIV-1 p24 production in the culture supernatant (Panel B).
Jurkat cells were stimulated with IFN α for 72 h. After 72 h cells were transfected with 2 μg of shRNA 228 against ADAR1 or control scramble shRNA 526 constructs for 48 h. After 48 h
cells were infected with 500 ng/ml of virus. 48 h after infection viral protein synthesis was monitored by measuring the p24 production in the culture supernatant (Panel C).
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structural proteins, Gag, Pol and Env proteins.
ADAR1 does not inhibit HIV-1 RNA synthesis
In order to determine whether the inhibition of HIV-1 protein syn-
thesis is due to inhibition of viral RNA synthesis we quantitated the
level of gag, pol and env RNA by real-time RT-PCR. Cellular RNA was
isolated from cells transfected with ADAR1 or control DNA in thepresence of pNL4.3 plasmid and subjected to real-time RT-PCR, as de-
scribed in Materials and methods. As shown in Fig. 4 the level of gag,
pol and env RNA was not diminished in the presence of ADAR1 ex-
pression as compared to cell not expressing ADAR1, whereas the pro-
duction of the HIV-1 p24 protein (data not shown) was signiﬁcantly
reduced in the presence of ADAR1 expression. These results led us
to conclude that the ADAR1-mediated antiviral effect was at a post
transcriptional step in the HIV-1 life cycle.
Fig. 3. HIV-1 viral protein synthesis in the presence of ADAR1. 293 T cells were co-transfected with pNL4.3 plasmid (0.1 μg), and ADAR1 (0.7 μg) or control empty vector (pcDNA 3.1, 0.7 μg). After 48 h and the supernatant was ﬁltered and
centrifuged at 220000 rpm for 1 h and the pellet was lysed with RIPA buffer. The transfected cells were also lysed with RIPA buffer and were subjected toWestern blot analysis. Western blot analysis of viral supernatant was done using HIV-1
infected patient's antisera (Panel A) and gp120 polyclonal antibody (Panel B). Number below panel B shows the relative amount of gp120 in the supernatant by the band density. Western Blot was also performed using the cell lysate from
the same experiment using HIV-1 infected patient's antisera as an antibody (Panel C) and gp120 polyclonal antibody (Panel D). Number below panel B shows the relative amount of gp120 in the infected cells. Expression of Nef protein in
presence and absence of ADAR1 in cell lysate was analyzed by Western Blot using anti-nef antibody (Panel E).
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Fig. 4. Effect of ADAR1 onHIV-1RNA synthesis. Viral gag, pol and envRNAwas quantitated in cells transfectedwith pNL4.3 in thepresence and absence of ADAR1DNAbyReal-time RT-PCR.
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HIV-1 rev RNA is involved in the post-transcriptional modiﬁcation
of the HIV proteins (Felber et al., 1989; Hadzopoulou-Cladaras et al.,
1989; Malim and Cullen, 1993; Malim et al., 1989b; Malim et al.,
1990; Rosen et al., 1988). Furthermore, Env and Vif expressions are
required for infectivity of the virus (Buchbinder, 1990; Desrosiers
et al., 1998; Simon et al., 1998; Simon et al., 1999). Therefore, we an-
alyzed rev, env and vif RNA for A-to-G mutations, a hallmark of the
editing function of ADAR1. For this purpose, 293 T cells were trans-
fected with pNL4.3 construct in the presence and absence of ADAR1
expression. Following 48 h post transfection cellular RNA was isolat-
ed and was ampliﬁed by RT-PCR using gene speciﬁc primer pairs.
PCR products were cloned in pcDNA3.1 vector and sequenced. As
shown in Fig. 5A speciﬁc A-to-G mutations were noted in the revFig. 5. ADAR1 induced mutations in the HIV-1 rev RNA. 293 T cells were transfected with pN
jected to RT PCR ampliﬁcation. Amplicons were cloned in pcDNA3.1 and 12–25 clones were
the nucleotide sequence of rev region of HIV-1 genome (Panel A). Four sequences are the rep
of HIV-1 rev region in the presence and absence of ADAR1 (Panel B).sequences. These mutations were speciﬁcally observed in the ﬁrst
exon of rev at positions 5998, 6011, 6017, 6036, and N terminus of
Rev Response Element (RRE) binding site (positions 8413 and 8438)
of rev. These mutations caused signiﬁcant amino acid changes, like ar-
ginine to glycine, and glutamine to arginine in the RRE binding site
(Fig. 5B). No A-to-G mutations were observed in the LTR, vif, and tat
regions of HIV-1 genome (data not shown).
We then investigatedwhether therewas an association between the
level of ADAR1-mediated inhibition of protein synthesis and the fre-
quency of ADAR1-induced mutations in rev RNA. Cells transfected
with a lower amount of ADAR1 plasmid (0.2 μg/μl) resulted in a lower
level of inhibition of viral protein synthesis (36%) and a lower frequency
(30%) of clones with A-to-G mutations in rev gene. In contrast, cells
transfected with a higher amount of ADAR1 plasmid (1 μg/μl) led to aL4.3 and the ADAR1 plasmid DNAs. The RNA isolated from transfected cells were sub-
picked (in the presence and absence of ADAR1) and sequenced. Mutational analysis of
resentative of all clones with identical mutations. Comparison of amino acid sequences
271N. Biswas et al. / Virology 422 (2012) 265–277higher level of inhibition (80%) of viral protein synthesis and to a higher
frequency (56%) of clones with A-to-G mutations in the rev gene.
Since in the presence of ADAR1 virus infectivity was diminished
and there was inhibition of viral Env synthesis, we also examined
the editing activity of ADAR1 on env RNA, in 293 T cells. Since the
HIV-1 env gene is of 2564 bp in length we analyzed the env sequences
in 4 segments: Segment 1(6221–6873), Segment 2 (6872–7521), Seg-
ment 3 (7522–8187), and Segment 4 (8188–8803). Speciﬁc A-to-G
mutations were located in 29 different places in env gene. No A-to-
G mutations were observed in the absence of ADAR1. It is noteworthy
that a number of these mutations were observed in the RRE (Rev Re-
sponse Element), a region needed for binding of Rev for its function,
and in variable region 2 (V2) and V4 region (Kowalski et al., 1987)
(Fig. 6).
Rev mutants rescue replication of HIV-1 Δrev
Todeterminewhether theRevmutantswere functional,we examined
the capacity of each mutants to rescue Rev function in rev deleted HIV-1
construct (pMrev(−)).The revmutant constructs pMrev(−) was derived
from an infectious proviral clone of HIV-1IIIB in which Rev in not synthe-
sized, but functionally active Tat is expressed. For this purpose 293 T
cells were co-transfected with 0.2 μg pMrev(−) construct and 0.3 μg
wild type rev ormutant rev-expressing plasmid. RLucwas used as a trans-
fection control. Virus-containing supernatants were collected approxi-
mately 48 h after transfection, and virus production was quantiﬁed by
p24production in cell culture supernatant by ELISA (Supplemental Fig. 4).
As expected in the absence of Rev, low level of viral protein syn-
thesis was observed which increased by 8-fold in the presence of
wild type Rev. Mutant constructs 3 and 4 also rescued viral protein
synthesis to wild type level. However, mutant constructs 1 and 2Fig. 6. ADAR induced mutations in HIV-1 env gene. Mutational analysis of the env region of H
pc DNA or ADAR1 constructs and RNA was isolated from infected cells. RT-PCR was done an
individually (Segment 1 (6221–6873), Segment 2 (6872–7521), Segment 3 (7522–8187), an
ence and absence of ADAR1 and sequenced. In case of env 24 sequences were computed indid not rescue the viral protein synthesis compared to wild type
Rev. Mutant 1 and 2 had mutations at position 6036 and in the RRE
binding region of Rev, respectively. Thus, these mutations in rev
that were induced by ADAR1 expression decreased Rev function.A-to-G mutation in RRE region in env affects the binding of rev
It is known that HIV-1 rev binds to the RRE region in env gene. Be-
cause ADAR1 induced speciﬁc A-to-G mutations were observed in
RRE binding region in rev we examined whether mutations in RRE
binding region have any effect in binding of rev to this RRE region
to env gene. For this purpose we used pDM128, a reporter plasmid de-
rived from the env region of HIV-1 SF2. The transcripts produced by
pDM128 harbor a single intron containing the CAT coding sequence,
which is excised when the RNA is spliced. Cells transfected with
pDM128 alone express only the spliced viral transcripts in the cyto-
plasm and, thus produce only trace levels of CAT enzyme activity.
Co-transfection with a plasmid encoding wild type Rev, however, per-
mits the unspliced transcripts to enter the cytoplasm, thereby in-
creasing CAT activity. 293 T cells were co-transfected with 0.6 μg
pDM128 construct and 8 μg wild type Rev or Rev mutant plasmids.
After 48 h post-transfection, cells were lysed and CAT assay was per-
formed on cell lysate (Fig. 7). There was a 45% inhibition in the CAT
activity in the case of mutants 1 and 2 compare to wild type. Expres-
sion of mutants 3 and 4 led to similar levels of CAT activity as com-
pared to wild type Rev expression. The binding activity to Rev to
the env RRE region were consistent with rescue activity of the mu-
tants, suggesting that A-to-G mutations in rev RRE present in mutants
1 and 2 decreased the binding of Rev to RRE, resulting in a defect in
functional (binding) activity of Rev.IV-1 genome in the presence and absence of ADAR1. 293 T cells were transfected with
d c DNA of env was cloned in pc DNA vector. Each segment of the env gene was cloned
d Segment 4 (8188–8803). 24 clones were randomly picked from each segment in pres-
to 11 groups.
Fig. 7. A-to-G mutation in RRE region in env affects the binding of Rev. 293 T cells were
transfected with 0.6 μg pDM128 construct with 8 μg wild type rev or mutants rev con-
structs 1, 2, 3 and 4. Cells were lysed after 48 h and CAT ELISA assay was performed.
Renilla luciferase plasmid was used to normalize the internal transfection efﬁciency.
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RNA transcripts from nucleus to cytoplasm
It is known that the Rev protein is involved in controlling synthe-
sis of the structural proteins Gag, Pol and Env protein by facilitating
transport of their partially and fully spliced message into the cyto-
plasm (Felber et al., 1989; Malim et al., 1989b). We examined wheth-
er the ADAR1 induced A-to-G mutations in the rev inhibited transport
of partially spliced (4Kb) and fully unspliced RNA from nucleus to cy-
toplasm. 293 T cells were co-transfected with 0.1 μg of pNL4.3 and
0.5 μg control pcDNA or 0.5 μg ADAR1 DNA. After 48 h of transfection
RNA and protein from cytoplasm and nuclei were isolated. ToFig. 8. A-to-G mutations introduced by ADAR1 affects the export of gag, pol and env RNA tran
and 0.5 μg control pc DNA or 0.5 μg ADAR1. After 48 h PARIS kit (Ambion) was used to isolate
pol and env RNAwas performed using RNA isolated from cytoplasm and nucleus fraction. Thedetermine whether there was any cross-contamination between
RNA in isolated nuclear and cytoplasmic fractions, we examined the
presence of β-actin, a cytoplasmic protein, and histone 3, a nuclear
protein. Western Blot analysis (data not shown) showed no contam-
ination between the nuclear and cytoplasmic fraction. Real-time RT-
PCR of gag, pol and env RNA was performed using RNA isolated from
both the cytoplasmic and nuclear fractions. The ratio of nuclear
RNA:cytoplasm RNA was calculated for cells transfected with pcDNA
(control) or ADAR1 plasmid. In general in the presence of ADAR1
there were more gag (approximately 3-fold), pol and env (approxi-
mately 4-fold) RNA copies present in the nucleus to those measured
in the cytoplasm (Fig. 8).
These data together indicate that ADAR1-induced mutations in rev
cause inefﬁcient binding of rev to the RRE region of HIV-1 which leads
to reduced transport of HIV-1 RNA from nucleus to cytoplasm, result-
ing in inhibition of viral protein synthesis without any effect on viral
RNA synthesis.
A-to-G mutations in the proviral genome at positions 6036, 8413 and
8438 in rev gene affect viral protein synthesis
To conﬁrm that A-to-G mutations at positions 6036, 8413 and 8438
in the RRE binding region of rev is responsible for inhibition of viral pro-
tein synthesis and not viral RNA synthesis, we introduced these muta-
tions individually or together in the rev gene of an infectious proviral
construct (pNL4.3) by site directed mutagenesis andmeasured their ef-
fect on HIV viral protein synthesis. As shown in Fig. 9A a single A-to-G
mutation in positions 6036, 8413 and 8438 inhibited p24 production
by 50%, 80% and 45% respectively as compared to synthesis of wildscripts from nucleus to cytoplasm. 293 T cells were co-transfected with 0.1 μg of pNL4.3
RNA and protein from cytoplasm and nucleus of transfected cells. Real-time PCR of gag,
ratio of nuclear RNA: cytoplasmic RNAwas plotted for both control pcDNA and ADAR1.
Fig. 9. A-to-G mutations in the proviral genome at positions 6036, 8413 and 8438 affect the synthesis of viral protein. A-to-G mutations were introduced at positions 6036, 8413 and
8438 (single, double and triple) using site directed mutagenesis kit (Stratagene). 293 T cells were transfected with 0.1 μg mutant constructs and Renilla Luciferase plasmid. Viral
protein synthesis was monitored by measuring HIV p24 in culture supernatant (Panel A) and intracellular HIV p24 production (Panel B). Viral gag RNA was quantitated in cells
transfected with mutant constructs by Real-time RT-PCR (Panel C).
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8438 inhibited virus production by 75% as compared to wild type
virus. All three mutations were able to inhibit 98% of the viral protein
synthesis. Similarly, intracellularHIV-1 p24was also inhibited to similar
levels in these revmutants (Fig. 9B). However, there was no change in
intracellular viral gag RNA levels in the cells transfected with any of
these mutants (Fig. 9C).
A catalytic domain of ADAR1 is critical for inhibition of HIV-1protein syn-
thesis and production of infectious virus
Human ADAR1 has a Z-DNA binding domain, three dsRNA binding
domains and a conserved deaminase domain (Eckmann et al., 2001;
Ryter and Schultz, 1998). Fig. 10A shows a schematic diagram of
ADAR1 and ADAR1 mutant constructs used to determine which do-
mains of ADAR1 that are critical for antiviral activity (Fig. 10A)
(Eckmann et al., 2001; Ryter and Schultz, 1998). Fig. 10B shows the ex-
pression of full length ADAR1, ADAR1ΔC (catalytic domain deletionmu-
tant) and ADAR1 E-to-A (single amino acid change from glutamic acid
to alanine in catalytic domain) mutant clones. ADAR1ΔM construct
(double stranded RNA binding domain) did not show expression as
the ADAR1 antibody used was targeted to the DRBM domain. To deter-
mine which domains are involved in inhibiting viral protein synthesis
and infectivity, 293 T cells were co-transfected with either full length
ADAR1 or ADAR1 deletion constructs in the presence of pNL4.3 DNA.
Virus-containing supernatants were collected 48 h post-transfection,
and virus production was quantiﬁed. As shown in Fig. 10C, ADAR1
with a deletion in the deaminase domain (ADAR1ΔC) or a catalytic do-
main mutation (ADAR1 E-to-A) signiﬁcantly diminished inhibition of
extracellular p24 production, (Fig. 10C) intracellular p24 level (datanot shown) and infectivity of HIV-1 produced from the cells (data not
shown). In contrast, ADAR1ΔM, which has a deletion in double strand-
ed RNA binding domain, showed inhibition of extracellular (Fig. 10C)
and intracellular p24 synthesis, (data not shown) aswell as reduced in-
fectivity of HIV-1 produced from the cells (data not shown). These mu-
tants behave similar to wild type ADAR1.
From these experiments, it is concluded that catalytic motif of
ADAR1 deaminase domain, but not the ds RNA binding domain is crit-
ical in mediating inhibition of HIV-1 protein synthesis and production
of infectious virus. To examine the effect of these ADAR1 deletion
construct on viral RNA synthesis, intracellular levels of HIV-1 viral
gag, pol and env RNA were measured in cells transfected with
pNL4.3 and ADAR1, ADAR1ΔC, ADAR1ΔM and ADAR1 E-to-A DNA or
control DNA by the Real-time RT-PCR. As shown in supplemental
Fig. 5, no signiﬁcant changes in the level of gag, pol and env RNA
were observed in the presence of ADAR1 and its mutant constructs
(compared to pcDNA vector control). These results reconﬁrm our pre-
vious data described above that ADAR1 acts at a post transcriptional
step of viral replication.
Since the catalytic domain of ADAR1 appears to be involved in in-
hibition of viral protein synthesis we investigated whether this do-
main is also responsible for A-to-G mutation in rev. Therefore we
analyzed mutations in rev RNA isolated from cells transfected with
wild type ADAR1or the various deletion constructs described in
Fig. 10A. No mutations were observed when ADAR1ΔC, ADAR1 E-to-
A, or the control was expressed. However, mutations were observed
in the presence of wild type ADAR1 or ADAR1ΔM expression, pre-
sumably due to the presence of a functional catalytic domain in
both (Fig. 10E).
Fig. 10. Evaluation of domain of ADAR1 critical for inhibition of HIV-1 protein synthesis and production of infectious virus. Schematic representation of full length human ADAR1
and ADAR1 mutant constructs (Panel A) and their expression (Panel B). 0.1 μg of pNL4.3 plasmid was co-transfected with 1 μg of ADAR1 and different domain mutant constructs of
ADAR1. The Renilla Luciferase expression was used as transfection normalization control (data not shown). Extracellular p24 production in presence and absence of ADAR1 and its
mutant constructs (Panel C). Mutational analysis of the rev region of HIV-1 in presence of wild type and ADAR1 mutant constructs (Panel D).
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In our current study, we provide evidence for the inhibitory effect
of ADAR1 on HIV-1 protein synthesis and infectivity using a transfec-
tion system. Our data show that ADAR1 inhibits HIV-1 protein syn-
thesis irrespective of viral tropisms or clades. ADAR1 mediated HIV-
1 inhibition was observed in different cell lines, like 293 T, HeLa and
Jurkat T cell line and primary CD4+ T cells isolated from peripheral
blood. Furthermore we have shown that antiviral activity of ADAR1
was not only against transfected HIV-1, but it also affected HIV-
1infectivity. Such inhibition of viral protein synthesis was observed
with as little as 0.2 μg of ADAR1 DNA in 293 T cells .Additionally, we
have shown that, antiviral activity of ADAR1 can be blocked by
shRNA against ADAR1 p150, demonstrating speciﬁcity of ADAR1 in-
duced inhibition of HIV-1 protein synthesis.
Our results indicate that ADAR1 mediated inhibition of viral pro-
tein synthesis occurs at a post- transcriptional step of viral replica-
tion, namely at the step of nuclear export of viral gag, pol and env
mRNA. This effect of ADAR1 on the nuclear export was seen to be
due to ADAR1-induced A-to-G mutations on rev and RRE region on
env. These ADAR1 induced A-to-G mutations on HIV-1 rev and env
mRNA correlated with inhibition of virus replication, production
and infectivity. HIV-1 env overlapping with rev, had the same A-to-
G mutations which were observed in case of rev. However, no such
ADAR1 induced mutation was observed in LTR, vif and tat regions. It
is known that ADAR1 prefers certain secondary structure for its enzy-
matic action. Therefore differential susceptibility of certain region for
mutation could be due to some structural speciﬁcity of the RNA in
that region .It is especially puzzling why the sequences in tat that
overlaps with rev did not show any mutation. It is possible that the
overall secondary structure of tat interfered with the editing function
of ADAR1 in the overlapping region due to some steric hindrance.Lack of ADAR1 induced mutation in LTR and tat is consistent with
our observation of no change in viral RNA in the presence of ADAR1.
Since ADAR1 inhibits HIV-1 viral protein synthesis and concomi-
tantly induces mutation in viral rev RNA, we examined the mecha-
nisms by which these mutations could perturb viral protein
synthesis. It is known that the Rev protein is involved in controlling
synthesis of the structural proteins by facilitating transport of their
mRNA from nucleus to cytoplasm (Felber et al., 1989; Malim et al.,
1989b) through binding of RNA binding domain in rev with Rev Re-
sponsive Element (RRE) which is present in all unspliced viral tran-
scripts of structural proteins (Bohnlein et al., 1991; Malim et al.,
1989a; Malim et al., 1991).
In this report we have shown that ADAR1-induced mutations in the
ﬁrst exon and NLS/RRE binding region of rev resulted in a decrease in
binding of rev to RRE and reduced transport of singly and multiple
spliced HIV-1 gag, pol and envmRNA fromnucleus to cytoplasm. Impor-
tance of these mutations have been further demonstrated by introduc-
tion into an infectious molecular clone of HIV-1 (pNL4.3 construct)
resulting in a decrease in viral protein synthesis with no change in
viral RNA synthesis. These data together indicate that ADAR1-induced
mutations in rev cause inefﬁcient binding of Rev to the RRE region of
HIV-1 which leads to reduced transport of unspliced and single spliced
HIV-1 mRNA from nucleus to cytoplasm, resulting in inhibition of viral
protein synthesis without any effect on viral RNA synthesis.
In addition to mutations in the rev RNA, we also observed ADAR1-
induced mutations in the sequence encoding the V2 and V4 regions of
gp120. This supports our observation that ADAR1 inhibits synthesis of
structural proteins without inhibiting synthesis of their mRNA. It is
known that constant loop 4 (C4) and variable loop 3 (V3) along
with V2 loop are important for viral entry process and therefore infec-
tivity of the virus (Kowalski et al., 1987). Therefore, these ADAR1-
induced mutations in HIV-1 env probably resulted in production of
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the virions. This supports our observation that virions secreted in the
presence of ADAR1 were non-infectious.
Phuphuakrat et al.(2008) and Doria et al.(2009) reported that ADAR1
enhanced the expression of HIV-1 proteins. However, Phuphuakrat et al.
(2008) found inhibition of production of infectious virus in the presence
ofADAR1,whileDoria et al., (2009) showedADAR1 inducedenhancement
of infectious virus production. Recently, Clerzius et al.(2009) have
reported that ADAR1 interacts with the interferon-induced protein kinase
during HIV-1 infection. It is unclear as to why our results are discrepant
with those of Doria et al.(2009) and Phuphuakrat et al.(2008).
Phuphuakrat et al.(2008) and Doria et al.(2009) did not provide any
adequate explanation for the observed ADAR1 induced enhancement of
viral protein synthesis. Phuphuakrat et al.(2008) did not explain clearly
the reason of the enhancement of viral replication. They stated that a
decrease in unspliced RNA in nucleus may have resulted in increased
nuclear RNA splicing. Furthermore, they commented that sequencing
around the RRE region in the ADAR1-overexpressing cells showed
some site-speciﬁc A-to-G editing at nucleotides 8164 to 8166, which
could provide an advantage in viral protein expression via an unknown
cis-acting element. However they did not provide evidence in support
of these hypotheses. Doria et al.(2009) have explained their observation
of ADAR1 induced enhancement by citing the paper by Clerzius et al.
(2009) which showed that ADAR1 inhibits the PKR kinase and thereby
suppresses protein synthesis by phosphorylating eIF-2a (Clerzius et al.,
2009). If that would have been the case we should have observed pro-
tein synthesis of all viral proteins. However our data show that ADAR1
had no effect on Nef or Tat protein synthesis.
Antiviral effect of ADAR1, on the other hand, makes sense from a bio-
logical and amechanistic point of view. ADAR1 is an interferon-inducible
protein involved in antiviral activity against a number of RNA viruses
(Patterson and Samuel, 1995), therefore, it is expected that ADAR1 will
have antiviral activity rather than enhancing activity. Viperin, another
interferon-inducible protein, has been shown to have anti-viral activity
against HCV and inﬂuenza virus (Helbig et al., 2005; Hinson and
Cresswell, 2009; Jiang et al., 2008). As mentioned earlier, ADAR1 has
been shown to have antiviral activity against a variety of RNA viruses
(Horikami and Moyer, 1995; Patterson and Samuel, 1995; Polson et al.,
1996; Sato et al., 2001). The hydrolytic deamination of adenosine to ino-
sine in completely or partially double-strandedRNAbyADAR1 affects pre
mRNA splicing, incorporates incorrect amino acid during translation, and
decreases the binding of RNA to protein. All of these changes are expected
to have deleterious effect on the function of viral protein and hence viral
protein synthesis. In this report we have conclusively proven that ADAR1
introduced mutations in the Rev Response Element (RRE) binding re-
gions of rev RNA inhibits binding of rev to the RRE region in the env and
inhibits transport of primary transcripts like gag, pol and env from the nu-
cleus to cytoplasm resulting in the inhibition of viral protein synthesis
without any effect on viral RNA synthesis. This result was further con-
ﬁrmed by introducing samemutations in rev of a proviral DNA producing
similar phenotype of viral inhibition, i.e., suppression of viral protein syn-
thesis without affecting viral RNA synthesis.
In summary, our data demonstrate that ADAR1 is an important cellu-
lar protein which inhibits HIV-1 protein synthesis by editing viral rev
RNA, thereby disabling transport of unspliced and singly spliced viral
mRNA from nucleus to cytoplasm. ADAR1 also inhibits infectivity of the
virus by editing viral env RNA. Therefore, ADAR1 constitutes a novel
multi-targeted cellular protein against HIV-1which can have therapeutic
implications.
Material and methods
Cell lines and DNA constructs
293 T (ATCC CRL-11268), TZM-bl (NIHAIDS research and reagent
program Catalog number 8129) and HeLa (NIHAIDS research andreagent program Catalog number 153) cell lines were cultured in
DMEM (Invitrogen Life Technologies) supplemented with 10% FBS
(HyClone), 1% penicillin, and 10 μg/ml streptomycin. The Jurkat
(ATCC®TIB-152TM) cell line was grown in RPMI-1640 medium con-
taining 10% FBS, 2 mM L-glutamine, 1% penicillin, and 10 μg/ml strep-
tomycin. CD8 depleted PBMC was isolated by immune-magnetic
beads coated with antibody to CD8 as described previously (Chen
et al., 2000; Chen et al., 1997).
Initial experiments were done using ADAR1 and ADAR1 mutant
constructs as described (Lai et al., 1995). Subsequently a new
ADAR1 construct made in pcDNA 3.1 vector was used. Sequence of
the ADAR1 was conﬁrmed by sequencing and found to be identical
to that described originally by Nishikura group (Lai et al., 1995).
ADAR1 ΔC is a deletion mutant construct where the catalytic domain
(nucleotide 839 bp to 1222 bp of ADAR1) is deleted. In case of ΔM
ADAR1, the double stranded RNA binding domain (from nucleotide
1689 bp to 2376 bp of ADAR1) was deleted. In E-to-A mutant con-
struct, a single point mutation in the catalytic domain at the position
917, from glutamic acid to alanine was made which abolishes the cat-
alytic activity of ADAR1 and was used for the experiment. Renilla Lu-
ciferase (RLuc) plasmid (Promega) was used as a transfection control
(Matthews et al., 1977). Infectious molecular clone pNL4.3 plasmid,
pNLAd8 and p89.6 were obtained from the NIHAIDS Research and Re-
agent Program. pIndie C plasmid was obtained from Dr. Masashi Tat-
sumi (Tokyo, Japan)(Mochizuki et al., 1999). pRev(−) construct was
obtained from NIH AIDS Research and Reagent Program (catalog
number 2086). pDM-128 and control plasmids were obtained from
Dr. Thomas Hope (Hope et al., 1990).Transfection and P24 ELISA
For transfection in 293 T cells, media containing plasmids
(pNL4.3/pNLAd8/p89.6, ADAR1 or control RLuc DNAs) and Lipofecta-
mine 2000 (2× of the amount of plasmid) were incubated together at
room temperature for 15–20 min, and added slowly to the wells con-
taining 1×106 million 293 T cells. After 4 h the media was replaced
with fresh media containing 10% fetal bovine serum. 5×106 million
HeLa cells were nucleofected with the Nucleofector Kit R (Amaxa)
in program I-13 when cells reached 70–80% conﬂuency (0.5–1×106
cells). Jurkat cells were also nucleofected with the same kit, using
program A-017. Five million CD8 T depleted PBMC were nucleofected
with the Human T cell Nucleofector solution (Amaxa) in program V-
024.
To measure the production of intracellular and extracellular virus
particles in the presence of ADAR1, 293 T cell was co-transfected with
cocktail comprising of pNL4.3 plasmid, different amount of ADAR1,
pcDNA 3.1 empty vector and 0.1 μg of RLuc plasmid. Virus-
containing supernatants were collected 48 h post-transfection, and
virus production was quantiﬁed by analyzing p24 production using
ELISA (Perklin Elmer p24 ELISA kit). To evaluate the Renilla luciferase
activity, cells were centrifuged at 5000 ×g for 10 min and lysed by in-
cubating with 100 μl 1× lysis buffer (Promega Duel luciferase report-
er assay kit, E1910) for 30 min. Thirty microliter cell lysate was mixed
with 100 μl Stop and Glo buffer and the luciferase activity was mea-
sured using Turner BioSystems Veritas™ MicroplateLuminometer.
To determine the intracellular virus production, 48 h post-
transfection, the cell pellet was washed with PBS twice, resuspended
in PBS containing 0.5% NP-40 and was incubated in ice for 10 min. The
mixture was centrifuged and supernatant used for p24 ELISA.Infectivity assay
Infectivity was determined in TZM-bl cell line as described previ-
ously (Derdeyn et al., 2000; Platt et al., 1998).
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3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide
(MTT) assay was performed to determine cell viability as previously
described (Mosmann, 1983).
Western blot
Cell lysates were prepared by lysing of 293 T cells with a lysis buff-
er (50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 0.5% Nonidet P40, 50 mM
NaF, 1 mM Na3VO4, 5 mM β-glycerophosphate, 1 mM dithiothreitol,
1 mM phenylmethylsulfonyl ﬂuoride) supplemented with a protease
inhibitor mixture (Sigma) on ice. Lysate was clariﬁed by centrifuging
at 14,000 ×g for 20 min and subjected to Western Blot analysis using
ADAR1 monoclonal antibody (1:2000 dilution from Santa Cruz (1:
500 dilution), anti-actin antibody (Sigma, 1:1000 dilution) and rabbit
anti-gp120 antibody (1:1000 dilution, Advanced Biotechnologies Inc)
or HIV-1 infected patient's antisera. Western Blot analysis was also
done using Rev antibody (1:1000 dilutions), and anti-Histone H3 an-
tibody (Santa Cruz, 1:500 dilutions).
CAT assay
293 T cellswere grown to 90% conﬂuency andwere transfectedwith
0.9 μg pDM-128 construct and 8ug of rev mutant construct. Cells were
lysed, and the amount of CAT protein was measured using a CAT
ELISA (Roche Applied Science, Indianapolis, IN) according to the manu-
facturer's instructions.
Site directed mutagenesis
Single nucleotide substitution (A-to-G) was introduced into rev
region of pNL4.3 using Stratagene (La Jolla, CA) quick-change site di-
rected mutagenesis kit in pNL4.3 proviral backbone.
RNA extraction, cloning and sequencing
RNA was isolated from transfected cells using RNA Bee (TEL-TEST,
INC) according to the manufacturer's instructions. The extracted RNA
was treated with RNase free DNase (Roche applied science) for
30 min followed by heat inactivation and subjected to RT-PCR. The
cDNA was synthesized using Superscript II reverse transcriptase
(Invitrogen) and random hexamar (IDT) in the presence of RNase in-
hibitor (Roche applied science). The rev and env PCR was done using
primers listed in Table 1. The PCR product was cloned in pcDNA 3.1
Vector (Invitrogen) between the restriction sites KpnI and XhoI for
rev and between Mlu1 and Xho1 for env. 12–25 clones were picked
from each plate and sequenced using ABI PRISM 3730 automated
DNA sequencer. For studies on rev 24 clones were sequenced and
they were found to grouped into 4 identical patterns of mutations,
whereas for env 24 clones were sequenced and they were found to
fall into 11 groups of identical patterns of mutations.Table 1
HIV-1 rev and env PCR primers.
Region Primer sequence
Rev Forward: ttggtaccatggcaggaagaagcggagaca
Reverse: tctcgagctattctttagttcctgactccaatactgtaggag
Env (1–652) Forward: cca cgc gta tga gag tga agg aga agt atc agc act
Reverse: cctcgaggggcacaataatgtatgggaattggc
Env (651–1300) Forward: ata cgc gtc ccg gct ggt ttt gcg att cta
Reverse: cctcgagcatacattgcttttcctacttcctgcc
Env (1301–1950 ) Forward: ata cgc gtc ccc tcc cat cag tgg aca aat
Reverse: cctcgaggctggttttgcgattcttca
Env (1951–2566) Forward: cca cgc gtc cag caa gaa aag aat gaa caa g
Reverse: gctcgagcttatagcaaaatcctttccaagccctgtcReal time RT-PCR analysis for quantiﬁcation of HIV-1 RNA from cells
20 ng of RNA was applied for reverse transcription using Taq-
Man® Reverse Transcription Reagents (Applied Biosystems) accord-
ing to the manufacture's protocol. A TaqMan® PCR was performed
in a 30 μl reaction mixture consisting of 5 μl cDNA with TaqMan®
Universal PCR Master Mix (Applied Biosystems), 900 nM each of for-
ward and reverse primers and 250nM FAM/TAMRA or FAM/MGB la-
beled probe. Real-Time RT PCR for the endogenous gene was
performed using Eukaryotic 18S rRNA Endogenous Control Reagents
(Applied Biosystems). ABI Prism 7000 Sequence Detection System
was used to carry out Real-Time PCR using the following cycling con-
dition: 50 °C for 2 min, 95 °C for 10 min, 45 cycles of 95 °C for 15 s and
60 °C for 1 min. The primers and probes used for the Real-Time PCR
were based on HIV-1 pNL4.3 sequence encoding the pol, gag and env
regions respectively (Supplemental Fig. 3). A serial dilution of
pNL4.3 plasmid DNA ranging from 10 to 106 copies was applied to
each PCR assay serving as HIV standard curve. An endogenous gene
standard curve containing serial diluted cellular RNA ranging from
100to 105 pg was included in each endogenous gene test. Both no
RT control and no template control were included in each assay to
monitor the genomic DNA contamination and guard against PCR
cross contamination, respectively. Each sample was run in triplicate.
ABS Prism 7000 SDS Software (Applied Biosystems) was used for
PCR data analysis and copy number estimation. To rule out the sam-
ple input and ampliﬁcation variations, HIV quantity in each sample
was normalized by the endogenous control, and the ﬁnal result was
expressed as HIV-1 RNA copies per microgram of total RNA.
Supplementary materials related to this article can be found on-
line at doi:10.1016/j.virol.2011.10.024.
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